Reata Pharmaceuticals (Reata Pharmaceuticals) 3-Year FCF Growth Rate : 12.00% (As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Reata Pharmaceuticals 3-Year FCF Growth Rate?

Reata Pharmaceuticals's Free Cash Flow per Share for the three months ended in Jun. 2023 was $-1.69.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 12.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -14.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 10 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Reata Pharmaceuticals was 34.20% per year. The lowest was -103.60% per year. And the median was 7.70% per year.

Competitive Comparison of Reata Pharmaceuticals's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Reata Pharmaceuticals's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reata Pharmaceuticals's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reata Pharmaceuticals's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Reata Pharmaceuticals's 3-Year FCF Growth Rate falls into.

Reata Pharmaceuticals 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Reata Pharmaceuticals (NAS:RETA) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Reata Pharmaceuticals 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Reata Pharmaceuticals's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Reata Pharmaceuticals (Reata Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reata Pharmaceuticals Inc (NAS:RETA) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

5320 Legacy Drive, Plano, TX, USA, 75024

Website

https://www.reatapharma.com

Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.

Executives

Steven Ryder	director	234 CHURCH STREET, SUITE 1020, NEW HAVEN CT 06510
Antal Rohit Desai	director, 10 percent owner	C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Rajiv Patni	officer: EVP, Chief R&D Officer	C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Bhaskar Anand	officer: SVP, Chief Accounting Officer	5320 LEGACY DRIVE, PLANO TX 75024
Manmeet Singh Soni	officer: COO, CFO and President	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Martin Edwards	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Dawn Carter Bir	officer: Chief Commercial Officer	C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DRIVE, SUITE 150, IRVING TX 75063
Christy J. Oliger	director	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Andrea Loewen	officer: SVP, Global Regulatory Affairs	C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Shamim Ruff	director	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Mcclellan William D. Jr.	director	C/O APOLLO ENDOSURGERY, INC., 1120 S., CAPITAL OF TEXAS HWY, BLDG. 1, SUITE 300, AUSTIN TX 78746
Michael D Wortley	officer: See Remarks	5320 LEGACY DRIVE, PLANO TX 75024
Meyer Colin John	officer: See Remarks	C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DR. SUITE 150, IRVING TX 75063
Biogen Inc.	other: See footnotes	225 BINNEY STREET, CAMBRIDGE MA 02142
Samina Khan	officer: SVP, Chief Medical Officer	5320 LEGACY DRIVE, PLANO TX 75024